U.S FDA has accepted IND application for COMP360 in PTSD, enabling the initiation of a Phase 2b/3 (COMP202) clinical trial in patients living with PTSD.

CMPS has benefited from positive phase 3 trial results and positive political developments since my last article. Click here ...

The company is also advancing commercial preparations for COMP360 in treatment-resistant depression (TRD), aiming to be ...

Shares of Compass Pathways Plc (NASDAQ:CMPS) rose about 3% in premarket trading on Wednesday after the company said the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS Pathways plc (NASDAQ:CMPS) has a ‘Buy’ or equivalent rating from the majority of ...

LONDON & NEW YORK, July 22, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaborati ...

Compass Pathways has entered its seventh U.S. strategic collaboration with Radial Health. Radial Health operates in five ...

COMPASS Pathways plc (CMPS) has filed for up to 40,089,163 share offering by selling stockholders.

COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. We recently ...